Formulation and characterization of mucoadhesive controlled release matrix tablets of captopril

dc.contributor.authorSaurí Duran, Jaume
dc.contributor.authorZachariah, M.
dc.contributor.authorMacovez, R.
dc.contributor.authorTamarit, J. Ll.
dc.contributor.authorMillán, D.
dc.contributor.authorSuñé Pou, Marc
dc.contributor.authorGarcía Montoya, Encarna
dc.contributor.authorPérez Lozano, Pilar
dc.contributor.authorMiñarro Carmona, Montserrat
dc.contributor.authorTicó Grau, Josep R.
dc.contributor.authorSuñé i Negre, Josep M. (Josep Maria)
dc.date.accessioned2020-07-14T10:39:12Z
dc.date.available2020-07-14T10:39:12Z
dc.date.issued2017-12
dc.date.updated2020-07-14T10:39:12Z
dc.description.abstractThe purpose of this study is to characterize controlled release matrix tablets of captopril and to find out the physicochemical properties that have an effect on the mucoadhesion process. The hydrophilic matrix tablets contain captopril, microcrystalline cellulose, barium sulfate, ascorbic acid, ethylcellulose N100, hydroxypropylmethylcellulose K15M, talc, magnesium stearate and colloidal silicon dioxide. The physicochemical properties of the formulations have been characterized using confocal microscopy, contact angle, and scanning electron microscopy. The potential mucoadhesion capabilities of the formulations were assessed measuring the surface free energy, the polar and dispersive forces, the spreading coefficients, the surface roughness, and the network structure of the hydrophilic matrix tablets. The results show that when the concentration of HPMC K15M increases, the spreading coefficients of polymer over mucus and mucus over polymer are more positive, thus increasing the contact between the matrix tablets with the mucus layer. The formulation that contains 15% of HPMC K15M is the formulation that presents a greater swelling capacity, a greater increase in surface roughness, and larger pores within the matrix. This formulation has a higher chain mobility and more free macromolecular chains able to diffuse in the mucus layer. Therefore, this formulation has the greatest potential mucoadhesion capability.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec675609
dc.identifier.issn1773-2247
dc.identifier.urihttps://hdl.handle.net/2445/168579
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.jddst.2017.03.009
dc.relation.ispartofJournal of Drug Delivery Science and Technology, 2017, vol. 42, p. 215-226
dc.relation.urihttps://doi.org/10.1016/j.jddst.2017.03.009
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationMembrana mucosa
dc.subject.classificationAdministració de medicaments
dc.subject.classificationAngiotensines
dc.subject.otherMucous membrane
dc.subject.otherAdministration of drugs
dc.subject.otherAngiotensins
dc.titleFormulation and characterization of mucoadhesive controlled release matrix tablets of captopril
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
675609.pdf
Mida:
2.78 MB
Format:
Adobe Portable Document Format